| 05/05 | Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromy.. | AQ |
| 04/28 | Ultomiris approved in the US for adults with generalised myasthenia gravis | AQ |
| 04/26 | BREAKING PMPRB NEWS : Another Win For Patients And The Innovative Pharmaceutical Industry | AQ |
| 04/11 | PMPRB UPDATE : PMPRB Is Accepting Intervener Leave Applications For SOLIRIS Re-hearing | AQ |
| 03/31 | SCC Leave Denied In Alexion Pharmaceuticals Inc v Canada (Attorney General) | AQ |
| 03/29 | PMPRB UPDATE : Supreme Court Refuses To Hear Appeal From Decision Restricting Canada's Pat.. | AQ |
| 03/18 | Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig.. | AQ |
| 03/17 | AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomir.. | AQ |
| 03/01 | AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement t.. | AQ |
| 02/10 | AstraZeneca sees $4B in COVID vaccine sales as revenue soars | AQ |
| 02/07 | PRIORITY NEWS : Referral To EBA Gives PCT Joint Applicants Reasons To Rejoice In 2022 | AQ |
| 01/25 | The 2022 PMPRB Outlook For Pharmaceutical Patentees In Canada | AQ |
| 01/10 | AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to.. | AQ |
| 01/07 | AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to.. | AQ |
| 2021 | M&A market remains strong despite decline in activity | AQ |
| 2021 | LIFE SCIENCES : Vavilov And The New Regulatory Environment | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Canada Seeks Leave To Appeal To The Supreme Court In PMPRB Exces.. | AQ |
| 2021 | OCULAR THERAPEUTIX : Announces appointment of karen-leigh edwards as senior vice president.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : FCA Remits Pricing Decision On ALEXION'S SOLIRIS To PMPRB | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotroph.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Canadian Drug Price Review Board Reined In | AQ |
| 2021 | "THIS COURT DOES NOT SIGN BLANK CHEQ : Federal Court Of Appeal Reverses Canada's Patented .. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Termination of Material Definitive Agreements (Form 8-K) | PU |
| 2021 | ALEXION PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Announces Positive Topline Results from Phase 3 Study of ULTOMIR.. | BU |
| 2021 | ALEXION PHARMACEUTICALS : AstraZeneca receives final regulatory clearance for the proposed.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : AstraZeneca receives clearance from the European Commission for .. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : EU regulators clear Astrazeneca's £28bn takeover of rival Alexio.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Caelum and Alexion Present Additional Phase 2 Data Reinforcing S.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Caelum and Alexion Present Additional Phase 2 Data Reinforcing S.. | BU |
| 2021 | ALEXION PHARMACEUTICALS : Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz).. | BU |
| 2021 | ALEXION PHARMACEUTICALS : AstraZeneca appoints Aradhana Sarin as new Chief Financial Offic.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : AstraZeneca and Alexion swap senior staff ahead of $39bn deal cl.. | AQ |
| 2021 | ASTRAZENECA : CMA to probe Covid vaccine maker AstraZeneca's £27.5bn US drug deal | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Submission of Matters to a Vote of Security Holders, Financial S.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations.. | BU |
| 2021 | ALEXION PHARMACEUTICALS : Announces Upcoming Data Presentations at the 26th European Hemat.. | BU |
| 2021 | ALEXION PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Finan.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Shareholders Approve Acquisition by AstraZeneca | BU |
| 2021 | ALEXION PHARMACEUTICALS : Shareholders Approve Acquisition by AstraZeneca (Form 8-K) | PU |
| 2021 | ALEXION PHARMACEUTICALS, INC. : Other Events (form 8-K) | AQ |
| 2021 | ALEXION : Q1 Earnings Snapshot | AQ |
| 2021 | ALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND .. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Reports First Quarter 2021 Results | BU |
| 2021 | ALEXION PHARMACEUTICALS : UPDATED Alexion to Report First Quarter 2021 Results on Friday, .. | BU |
| 2021 | ALEXION PHARMACEUTICALS : to Report First Quarter 2021 Results on Monday, May 3, 2021 | BU |
| 2021 | ALEXION PHARMACEUTICALS : AstraZeneca receives US clearance of proposed acquisition of Ale.. | AQ |
| 2021 | ALEXION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Announces Upcoming Data Presentations at the 73rd Annual Meeting.. | BU |
| 2021 | ALEXION PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K) | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Amendment to Annual Report (SEC Filing - 10-K/A) | PU |
| 2021 | ALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND .. | AQ |
| 2021 | ALEXION : 4Q Earnings Snapshot | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2020 Results | BU |
| 2021 | ALEXION PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2020 Results on Thursday,.. | BU |
| 2021 | ALEXION PHARMACEUTICALS : Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz.. | BU |
| 2021 | ALEXION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation .. | AQ |
| 2021 | ALEXION PHARMACEUTICALS : Alexion Highlights Commercial, Clinical and Financial Progress .. | BU |
| 2021 | ALEXION PHARMACEUTICALS : to Present at the 39th Annual J.P. Morgan Healthcare Conference | BU |
| 2020 | Alexion, Pluralsight rise; SolarWinds, Virgin Galactic fall | AQ |
| 2020 | ALEXION PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, .. | AQ |
| 2020 | ALEXION PHARMACEUTICALS : AstraZeneca to acquire Alexion, accelerating the Company's strat.. | AQ |
| 2020 | ASTRAZENECA : to acquire Alexion Pharmaceuticals Inc | AQ |
| 2020 | ASTRAZENECA : buying drug developer Alexion for $39 billion | AQ |
| 2020 | ALEXION PHARMACEUTICALS : AstraZeneca to Acquire Alexion, Accelerating the Company's Strat.. | BU |
| 2020 | ALEXION PHARMACEUTICALS : Receives Marketing Authorization from European Commission for Ne.. | AQ |
| 2020 | ALEXION PHARMACEUTICALS : Receives Marketing Authorization from European Commission for Ne.. | BU |
| 2020 | ALEXION PHARMACEUTICALS : to Present at Upcoming Virtual Investor Conferences | BU |
| 2020 | ALEXION PHARMACEUTICALS : Caelum and Alexion Announce Upcoming Data Presentations at the 6.. | BU |
| 2020 | ALEXION PHARMACEUTICALS : Announces Upcoming Data Presentations at the 62nd American Socie.. | BU |
| 2020 | ALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND .. | AQ |
| 2020 | ALEXION : 3Q Earnings Snapshot | AQ |
| 2020 | ALEXION PHARMACEUTICALS : Reports Third Quarter 2020 Results | BU |
| 2020 | ALEXION PHARMACEUTICALS : to Report Third Quarter 2020 Results on Thursday, October 29, 20.. | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
